Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00171587
Status:
COMPLETED
Last Update Posted:
2009-11-19
First Post:
2005-09-12
Brief Title:
Study of the Safety Tolerability Pharmacokinetics and Anti-tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase IB Open-label Dose-escalating Study of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Status:
COMPLETED
Status Verified Date:
2009-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to assess the safety tolerability dose limiting toxicity and maximum tolerated dose of vatalanib administered orally once daily in combination with capecitabine in patients with advanced cancer The study is also designed to determine the effect of vatalanib on the pharmacokinetics of capecitabine and the effect of capecitabine on the pharmacokinetics of vatalanib and to describe the anti-tumor activity of this combination regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None